Vanda’s VQW-765 Fails Phase III Trial for Social Anxiety Disorder
Event summary
- Vanda Pharmaceuticals’ Phase III trial (Study 3201) for VQW-765 in social anxiety disorder failed to meet its primary endpoint.
- The study involved 546 adults with social anxiety disorder across 30 U.S. clinical sites.
- VQW-765 did not show a statistically significant difference from placebo in reducing distress during the Trier Social Stress Test (TSST).
- The program is now on hold pending further analysis of the full dataset.
- VQW-765 is a novel alpha 7 nicotinic acetylcholine receptor (α7-nAChR) partial agonist licensed from Novartis.
The big picture
Vanda’s failure with VQW-765 highlights the challenges in developing non-sedating anxiolytic treatments for performance anxiety, a condition affecting over 20% of the U.S. population. The setback comes amid a broader industry push for innovative therapies targeting psychiatric disorders, where high unmet medical needs persist. Vanda’s ability to recover from this disappointment will be critical for maintaining its position as a key player in biopharmaceutical innovation.
What we're watching
- Pipeline Reassessment
- Whether Vanda will re-evaluate or pivot its VQW-765 development strategy following this setback.
- Investor Confidence
- How this failure impacts investor sentiment toward Vanda’s late-stage pipeline and broader R&D efforts.
- Competitive Landscape
- The pace at which competitors develop alternative treatments for performance anxiety, given the lack of FDA-approved options.
Related topics
